Actualising the power of antibody-drug conjugates as cancer therapeutics
European Pharmaceutical Review
AUGUST 24, 2022
generation products from fully delivering on their initial promise. However, the chemistries involved generate heterogeneous mixtures with ADCs having different DARs and clearance properties, and the payload is often prematurely cleaved during systemic circulation. necks inhibiting these first?generation
Let's personalize your content